Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Tokyo  >  DAIICHI SANKYO COMPANY, LIMITED    4568   JP3475350009

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

DAIICHI S : Notice on Details of the Share Options

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/12/2011 | 10:20am CEST
For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, President and CEO

(Code no.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges) Please address inquiries to Toshiaki Sai, Corporate Officer, Vice President, Corporate Communications Department

Telephone: +81-3-6225-1126

http://www.daiichisankyo.com/Notice on Details of the Share OptionsTOKYO, Japan (July 12, 2011) Daiichi Sankyo Company, Limited has announced that the subscription amount and other details of its No.5 share options were decided today. As previously announced, the Board of Directors had reached a decision on June 27, 2011 to issue the said share remuneration-type stock options (share options) to remunerate Directors (excluding Outside Directors) and Corporate Officers

1. Name of share options

Daiichi Sankyo Company, Limited No. 5 share options

2. Total number of share options

2,328 share options (100 shares per one share option) Breakdown

Six (6) Directors: 1,102 share options

Eighteen (18) Corporate Officers: 1,226 share options

3. Subscription amount for share options

111,200 yen per share option

(1,112 yen per share)

Reference

Date of Board of Directors resolution: June 27, 2011

###
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on DAIICHI SANKYO COMPANY, LI
07/12 Gspl in pact with ramagundam fertilizers
07/07 DAIICHI SANKYO : Enters Into Agreement with Servier Canada For Factor Xa Inhibit..
07/07 DAIICHI SANKYO : Researchers at Daiichi Sankyo Release New Data on Immunoglobuli..
07/05 DAIICHI SANKYO : UCB and Daiichi Sankyo will jointly commercialize lacosamide in..
07/05 DAIICHI SANKYO : Announces Details of Executive Share Options
07/04 DAIICHI SANKYO : 14th Takamine Memorial Daiichi Sankyo Prize Winner Announced
07/04 DAIICHI SANKYO : Announces Status Relating to Acquisition of Own Shares
07/01 DAIICHI SANKYO : 14th Takamine Memorial Daiichi Sankyo Prize Winner Announced
07/01 DAIICHI SANKYO : Announces Status Relating to Acquisition of Own Shares
06/30 DAIICHI SANKYO : Patent Application Titled "Method for Purifying Oligosaccharide..
More news
Sector news : Pharmaceuticals - NEC
01:30pDJSANOFI : 2Q 2016 -- Forecast
01:22p GSK outlook brightens as Brexit brings currency windfall
01:22p GSK chases next biotech asthma drug with 175 million pounds J&J deal
01:22p GlaxoSmithKline invests 275 million pounds in UK despite Brexit vote
10:22aDJBAYER : Reports Higher Second-Quarter Profit, Raises Guidance -- Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
07/15 Therapy Focus - Another Try For FGFR Inhibitors
07/14 Amgen and Daiichi Sankyo team up to market biosimilars in Japan
06/01 Nektar Therapeutics inks deal with Daiichi Sankyo for European rights to Onze..
04/26 Aviragen sells portion of Inavir royalty rights for $20M
04/18 BeiGene's BGB-283 shows positive effects in early-stage cancer study in diffi..
Advertisement
Financials ( JPY)
Sales 2017 911 714 M
EBIT 2017 -
Net income 2017 66 898 M
Finance 2017 307 538 M
Yield 2017 2,64%
P/E ratio 2017 25,38
P/E ratio 2018 26,62
EV / Sales 2017 1,63x
EV / Sales 2018 1,68x
Capitalization 1 794 153 M
More Financials
Chart DAIICHI SANKYO COMPANY, LI
Duration : Period :
DAIICHI SANKYO COMPANY, LI Technical Analysis Chart | 4568 | JP3475350009 | 4-Traders
Full-screen chart
Technical analysis trends DAIICHI SANKYO CO...
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 2 447  JPY
Spread / Average Target -3,3%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joji Nakayama President, CEO & Representative Director
Kentaro Takamura Vice President-Finance & Accounting Department
Glenn J. Gormley Senior Managing Executive Officer, Head-R&D
Masahiko Ohtsuki Executive Officer & Senior Manager-Research
Kazunori Hirokawa Representative Director, VP & GM-Administration
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
DAIICHI SANKYO COMPANY..1.50%17 001
JOHNSON & JOHNSON21.84%344 243
PFIZER INC.14.10%223 368
NOVARTIS AG-5.30%219 971
ROCHE HOLDING LTD.-9.99%218 902
MERCK & CO., INC.10.49%161 542
More Results